<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-01-15">15 January 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Hans</forename><surname>Pottel</surname></persName>
							<email>hans.pottel@kuleuven-kulak.be</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Public Health and Primary Care</orgName>
								<orgName type="institution">KU Leuven Campus Kulak Kortrijk</orgName>
								<address>
									<settlement>Kortrijk</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Delanaye</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Nephrology-Dialysis-Transplantation</orgName>
								<orgName type="institution" key="instit1">University of Lie `ge</orgName>
								<orgName type="institution" key="instit2">CHU Sart Tilman</orgName>
								<address>
									<addrLine>Lie `ge</addrLine>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elke</forename><surname>Schaeffner</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Public Health</orgName>
								<orgName type="institution">Charite ´University Hospital</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Laurence</forename><surname>Dubourg</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Exploration Fonctionnelle Re ´nale</orgName>
								<orgName type="institution" key="instit2">Groupement Hospitalier Edouard Herriot</orgName>
								<address>
									<settlement>Hospices Civils de Lyon, Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bjørn</forename><forename type="middle">Odvar</forename><surname>Eriksen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Metabolic and Renal Research Group</orgName>
								<orgName type="institution">UiT The Arctic University of Norway</orgName>
								<address>
									<settlement>Tromsø, Norway</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Toralf</forename><surname>Melsom</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Metabolic and Renal Research Group</orgName>
								<orgName type="institution">UiT The Arctic University of Norway</orgName>
								<address>
									<settlement>Tromsø, Norway</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edmund</forename><forename type="middle">J</forename><surname>Lamb</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Clinical Biochemistry</orgName>
								<orgName type="institution">East Kent Hospitals University NHS Foundation Trust</orgName>
								<address>
									<settlement>Canterbury</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><forename type="middle">D</forename><surname>Rule</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Division of Nephrology and Hypertension</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><forename type="middle">T</forename><surname>Turner</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Division of Nephrology and Hypertension</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><forename type="middle">J</forename><surname>Glassock</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Emeritus Professor of Medicine</orgName>
								<orgName type="institution">Geffen School of Medicine at UCLA</orgName>
								<address>
									<settlement>Laguna Niguel</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vandre</forename><surname>´a De Souza</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Universidade de Caxias do Sul -Programa de P os Graduac ¸ão em Ciências da Sa ude</orgName>
								<address>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luciano</forename><surname>Selistre</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Universidade de Caxias do Sul -Programa de P os Graduac ¸ão em Ciências da Sa ude</orgName>
								<address>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">Pontif ıcia Universidade Cat olica do Rio Grande do Sul</orgName>
								<address>
									<settlement>Porto Alegre, Brazil</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karolien</forename><surname>Goffin</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Nuclear Medicine &amp; Molecular Imaging</orgName>
								<orgName type="institution">University Hospital Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Steven</forename><surname>Pauwels</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Cardiovascular Sciences</orgName>
								<orgName type="institution">University Hospital Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Department of Laboratory Medicine</orgName>
								<orgName type="institution">University Hospital Leuven</orgName>
								<address>
									<addrLine>14 Service de Ne ´phrologie</addrLine>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution" key="instit1">Dialyse et Transplantation Re ´nale</orgName>
								<orgName type="institution" key="instit2">Ho ˆpital Nord</orgName>
								<orgName type="institution" key="instit3">CHU de Saint-Etienne</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Mariat</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Flamant</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Renal Physiology</orgName>
								<orgName type="institution" key="instit1">Ho ˆpital Bichat</orgName>
								<orgName type="institution" key="instit2">AP-HP and Paris Diderot University</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Natalie</forename><surname>Ebert</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Public Health</orgName>
								<orgName type="institution">Charite ´University Hospital</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-01-15">15 January 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">C95B953C122486A166C194C422B6A954</idno>
					<idno type="DOI">10.1093/ndt/gfw425</idno>
					<note type="submission">Received: 22.1.2016; Editorial decision: 12.5.2016 Received: 23.9.2016; Editorial decision: 6.11.2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Methods.</s><s>Based on an evaluation of the serum cystatin C (ScysC) distribution, we defined normalization constants for ScysC (Q cysC ¼ 0.82 mg/L for ages &lt;70 years and Q cysC ¼ 0.95 mg/L for ages !70 years).</s><s>By replacing Scr/Q crea in the FAS crea equation with ScysC/Q cysC , or with the average of both normalized biomarkers, we obtained new ScysC-based (FAS cysC ) and combined Scr-/ScysC-based FAS equations (FAS combi ).</s><s>To validate the new FAS cysC and FAS combi we collected data on measured GFR, Scr, ScysC, age, gender, height and weight from 11 different cohorts including n ¼ 6132 unique white subjects (368 children, aged 18 years, 4295 adults and 1469 older adults, aged !70 years).</s><s>Results.</s><s>In children and adolescents, the new FAS cysC equation showed significantly better performance [percentage of patients within 30% of mGFR (P30) ¼ 86.1%] than the Caucasian Asian Paediatric Adult Cohort equation (P30 ¼ 76.6%; P &lt; 0.0001), or the ScysC-based Schwartz equation (P30 ¼ 68.8%; P &lt; 0.0001) and the FAS combi equation outperformed all equations with P30 ¼ 92.1% (P &lt; 0.0001).</s><s>In adults, the FAS cysC equation (P30 ¼ 82.6%) performed equally as well as the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI cysC ) (P30 ¼ 80.4%) and the FAS combi equation (P30 ¼ 89.9%) was also equal to the combined CKD-EPI equation (P30 ¼ 88.2%).</s><s>In older adults, FAS cysC was superior (P30 ¼ 88.2%) to CKD-EPI cysC (P30 ¼ 84.4%; P &lt; 0.0001) and the FAS combi equation (P30 ¼ 91.2%) showed significantly higher performance than the combined CKD-EPI equation (P30 ¼ 85.6%) (P &lt; 0.0001).</s><s>Conclusion.</s><s>The FAS equation is not only applicable to all ages, but also for all recommended renal biomarkers and their combinations.</s></p><p><s>Keywords: all ages, all renal biomarkers, combined FAS equation, cystatin C, serum creatinine</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>I N T R O D U C T I O N</head><p><s>Serum creatinine (Scr)-based estimating glomerular filtration rate (eGFR) equations are commonly used and reported when Scr is measured.</s><s>Despite the worldwide acceptance of isotope dilution mass spectrometry (IDMS)-standardized Scr assays, Scr-based eGFR equations are still relatively imprecise <ref type="bibr">[1]</ref>.</s><s>Also, different equations are proposed for children, adults and older adults as most equations lack continuity and accuracy across the full age spectrum.</s></p><p><s>We recently published a Scr-based full-age-spectrum (FAS crea ) equation <ref type="bibr" target="#b0">[2]</ref> that has been validated in a large number of healthy and kidney-diseased white individuals (n ¼ 6870) including 735 children, 4371 adults and 1764 older adults against measured GFR (mGFR) and using IDMS-equivalent Scr.</s><s>The FAS crea equation showed improved validity and continuity across the full age spectrum and was less biased and more accurate than the currently recommended Scr-based eGFR equations.</s></p><p><s>The FAS equation is based on three fundamental assumptions:</s></p><p><s>• The average GFR for healthy populations (children, adolescents and young adults) is equal to a value of 107.3 mL/ min/1.73</s><s>m 2 after kidney function matures (around 2 years of age) until the age of 40 years.</s><s>This assumption is also supported by the results of a recent meta-analysis in living kidney donors <ref type="bibr" target="#b1">[3]</ref>.</s><s>• The age decline of GFR begins at around 40 years.</s></p><p><s>• GFR and population-normalized Scr (Scr/Q crea ) are inversely related (Q crea being the mean or median Scr concentration of the corresponding age-/sex-matched healthy population).</s></p><p><s>These three assumptions have led to the construction of the simple age-knotted FAS crea equation, which takes the form <ref type="bibr" target="#b0">[2]</ref>:</s></p><formula xml:id="formula_0">FAS crea ¼ 107:3 SCr Q crea Â 0:988 AgeÀ40 ð Þ when age &gt; 40 years h i :</formula><p><s>The equation is simple and intuitive and can be easily explained: when Scr/Q crea deviates from '1', the eGFR will deviate from the average value of 107.3 mL/min/1.73</s><s>m 2 .</s><s>Scr/Q crea , for every healthy age-/sex-matched population, is normally distributed (Gaussian distribution) around the mean of '1' (a consequence of the definition of Q crea ).</s><s>It has been shown that the 2.5th percentile (Pct) ¼ 0.67 and the 97.5th</s><s>Pct ¼ 1.33, or, equivalently, the standard deviation (SD) is 0.1683 <ref type="bibr" target="#b0">[2]</ref>.</s></p><p><s>Serum cystatin C (ScysC) is considered to be a potential alternative to Scr for estimating GFR <ref type="bibr" target="#b2">[4]</ref>, especially since a certified reference cystatin C material became available in 2010, allowing standardization of ScysC assays <ref type="bibr" target="#b3">[5]</ref>.</s></p><p><s>In this article, we demonstrate that the last assumption (that GFR is inversely related to the normalized Scr biomarker) also applies to ScysC, if properly normalized.</s><s>We show that the FAS crea equation can be transformed into a ScysC-based FAS equation (FAS cysC ) and a combined Scr-/ScysC-based FAS equation (FAS combi ), by simply replacing the normalized Scr (Scr/Q crea ) by ScysC/Q cysC or by the combination of Scr/Q crea and ScysC/Q cysC [i.e. the (weighted) average of Scr/Q crea and ScysC/Q cysC ], where Q cysC is the normalization factor for ScysC.</s></p><p><s>In the first part of this study, we give a rationale for choosing the normalization factor Q cysC for ScysC.</s><s>Next, we validate the FAS cysC and FAS combi equation against mGFR and compare the performance of these equations with the currently recommended and most used eGFR equations (Schwartz cysC <ref type="bibr" target="#b4">[6]</ref>, Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI cysC ) <ref type="bibr" target="#b2">[4]</ref>, Caucasian Asian Paediatric Adult Cohort equation (CAPA) <ref type="bibr" target="#b5">[7]</ref>, combined CKD-EPI combi <ref type="bibr" target="#b2">[4]</ref> and BIS2 <ref type="bibr" target="#b6">[8]</ref>).</s><s>Finally, we evaluate the performance of all FAS equations (by varying the weighting factors for the normalized biomarkers) in all age groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>M A T E R I A L S A N D M E T H O D S</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overview of study design and participants</head><p><s>We collected data from 11 cohorts, forming a representative sample of the general population and renal disease patients.</s><s>For the same six cohorts (Saint-Etienne, Tromsø, Rochester and</s></p><formula xml:id="formula_1">| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |</formula><p><s>Minnesota for adults; Kent and Berlin for older adults <ref type="bibr" target="#b0">[2]</ref>) that were used for the validation of the FAS crea equation, we additionally collected the ScysC results.</s><s>The other cohorts used in the previous validation did not have ScysC data available, and, therefore, we collected data of new cohorts.</s><s>For children, adolescents and young adults (&lt;21 years), one cohort came from the University Hospital in Leuven (n ¼ 114), and one from Lyon (n ¼ 695).</s><s>Both cohorts contained children and adolescents with established renal pathologies.</s><s>The data from Leuven contained single-time point measurements per child and the data from Lyon (n ¼ 695) were from 259 children with serial measurements over a period of several years, but we used the first measurement only.</s><s>We further collected data from a cohort of healthy and renal disease adults from Paris (n ¼ 603), from Lyon (n ¼ 598) and from the Chronic Renal Insufficiency Cohort (CRIC; n ¼ 3939) <ref type="bibr" target="#b7">[9]</ref>, which we restricted to whites only (n ¼ 1824) and to the first visit where all required variables were available (n ¼ 674).</s><s>All datasets were centralized by the first author for data analysis.</s><s>This retrospective non-interventional study was approved by the Institutional Ethical Board of the University Hospital of Leuven, Belgium.</s></p><p><s>In total, we collected data on mGFR, Scr, ScysC, age, gender, height and weight for n ¼ 6132 participants (n ¼ 368 children aged between 1 and 18 years; n ¼ 4295 adults aged between 18 and 70 years and n ¼ 1469 older adults aged !70 years).</s></p><p><s>We further used a separate cohort (n ¼ 1333) from the Berlin Initiative Study <ref type="bibr" target="#b6">[8]</ref> of apparently healthy older subjects to study the age dependency of the ScysC distribution.</s><s>This cohort was obtained from 2069 subjects (2069 baseline samples and 1693 follow-up samples) aged &gt;70 years (Berlin residents), which we reduced to a subset of 1333 individuals who were defined as apparently healthy; i.e. no history of myocardial infarction, no history of stroke, not on dialysis, not deceased between first and second follow-up study visit, no albuminuria (ACR &lt;30 mg/g), arterial blood pressure &lt;160/90 mmHg.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>The new FAS equation(s).</s><s>The form of the FAS crea equation was maintained, but Scr/Q crea is replaced by S cysC /Q cysC :</s></p><formula xml:id="formula_2">FAS cysC ¼ 107:3 ScysC Q cysC Â 0:988 AgeÀ40 ð Þ when age &gt; 40 years h i :</formula><p><s>By extending the same concept, we used the weighted average of the two normalized biomarkers Scr/Q crea and ScysC/ Q cysC , leading to the general form of:</s></p><formula xml:id="formula_3">FAS combi ¼ 107:3 a Â Scr Q crea þ 1 À a ð ÞÂ ScysC Q cysC Â 0:988 AgeÀ40 ð Þ when age &gt; 40 years h i :</formula><p><s>The coefficient 'a' in the denominator may be considered as a weighting factor for the normalized renal biomarkers.</s><s>In case a ¼ 1, the FAS equation depends entirely on Scr/Q crea and equals the FAS crea equation; in case a ¼ 0, the FAS equation becomes the ScysC-based FAS cysC equation.</s><s>In all other situations for 0 &lt; a &lt; 1, the equation is a combined Scr/ScysC equation.</s><s>For a ¼ 0.5, the denominator is equal to the average of both normalized biomarkers.</s><s>We further discuss the influence of a in the 'Results' section.</s></p><p><s>mGFR, Scr and cystatin C assays.</s><s>A summary of the methods used in the different collaborating centres is given in Tables <ref type="table" target="#tab_1">1 and 2</ref>. Direct GFR measurements were obtained with different reference methods as described previously <ref type="bibr" target="#b0">[2,</ref><ref type="bibr" target="#b8">10]</ref>.</s><s>Scr was measured with an enzymatic assay, equivalent to IDMS, or directly with IDMS, or recalculated to the enzymatic assay, in all centres.</s><s>ScysC was measured with the calibrated particleenhanced nephelometric (PENIA) method of Siemens in Saint-Etienne, Berlin and partially in Lyon.</s><s>The ScysC measurements for the CRIC Study were done with the non-calibrated PENIA assay of Siemens, but calculated back to the certified reference material, as previously described <ref type="bibr" target="#b2">[4]</ref>.</s><s>The non-calibrated PENIA assay of Siemens was also used in Rochester, Kent, and partially in Lyon, and the results were recalculated to the certified reference standard, using the multiplication factor in Rochester <ref type="bibr" target="#b9">[11]</ref> and in Lyon and Kent <ref type="bibr" target="#b10">[12]</ref>, according to the manufacturer's specifications.</s><s>Tromsø used the non-calibrated (with back calculation) and Leuven used the calibrated particleenhanced turbidimetric (PETIA, Tina quantV R ) assay of Roche (Tables <ref type="table" target="#tab_1">1 and 2</ref>).</s></p><p><s>eGFR equations.</s><s>The new FAS cysC equation and the FAS combi equation were compared and validated against mGFR and against the currently available and recommended eGFR equations listed in Table <ref type="table">3</ref>.</s></p><p><s>Statistical analysis.</s><s>The performance statistics are presented as constant bias (mean of eGFR-mGFR) and proportional bias (mean of eGFR/mGFR), root mean square error (RMSE) of prediction, Lin's concordance correlation coefficient (Lin's CCC, which is a measure of both correlation and agreement as it evaluates the degree to which pairs of observations fall on the identity line), P10 and P30 (the percentage of subjects within 10% and 30% of mGFR), for the different age groups, total and in subgroups according to mGFR &lt;60 and !60 mL/min/1.73</s><s>m 2 .</s></p><p><s>McNemar's test is used to compare P30 among equations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R E S U L T S</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Description of the cohorts</head><p><s>Summary statistics for the patient characteristics of the 11 cohorts are given in Tables <ref type="table" target="#tab_3">4 and 5</ref>, and are described in Supplementary data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rationale for Q cysC values for ScysC</head><p><s>To define normalization factors for ScysC we searched the literature for normal reference ranges and we investigated whether these ranges depend on age or gender differences.</s><s>We realized that the literature before the year 2010 was based on non-standardized cystatin C assays, but, in general, ScysC is independent of age (up to age 70 years) and gender in children, adolescents and adults <ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref>, although there might be small</s></p><formula xml:id="formula_4">| | | | | | | | | | | | | | | | | | | | | |</formula><p><s>differences between sexes and races <ref type="bibr" target="#b15">[17]</ref>.</s><s>We used the value of 0.82 mg/L as the normalization factor, as it is the middle of the normal reference interval for children, adolescents and adults up to $70 years (and in line with the manufacturer's information on reference ranges) <ref type="bibr" target="#b6">[8,</ref><ref type="bibr" target="#b16">18]</ref>.</s><s>The ScysC-based CKD-EPI equation normalized ScysC by 0.80 for both males and females <ref type="bibr" target="#b2">[4]</ref>, a value that is close to the proposed value of 0.82 in this study.</s><s>The new CAPA equation does not have a gender factor in the equation, suggesting that the same Q cysC normalization constant can be used for both sexes <ref type="bibr" target="#b5">[7]</ref>.</s><s>For older adults, we could not find normal reference ranges in the literature.</s><s>In our dataset of 1333 apparently healthy older persons aged &gt;70 years from the Berlin Initiative Study, we modelled Q cysC as a linear function of age: <ref type="figure" target="#fig_2">1</ref>).</s><s>At the age of 67.5 years, the corresponding value of Q cysC ¼ 0.82.</s><s>For mGFR, a renal clearance, all other methods are plasma clearance methods.</s><s>mGFR is indexed for body surface area using the Dubois formula.</s><s>Table <ref type="table">3</ref>. eGFR equations for the performance comparisons Scr-based equations Schwartz crea <ref type="bibr" target="#b13">[15]</ref> eGFR ¼ 0.413 Â Ht/Scr CKD-EPI <ref type="bibr" target="#b14">[16]</ref> eGFR ¼ 141 Â min(Scr/j) a Â max(Scr/j) À1.209 Â 0.993 Age Â (1.018 if female) j ¼ 0.7 for females and 0.9 for males; a ¼ À0.329 for females and À0.411 for males ScysC-based equations Schwartz cysC <ref type="bibr" target="#b4">[6]</ref> eGFR ¼ 40.6 (1.8/ScysC) 0.93 CAPA <ref type="bibr" target="#b5">[7]</ref> eGFR ¼ 130 Â ScysC À1.069 Â Age À0.117 -7 CKD-EPI cysc <ref type="bibr" target="#b2">[4]</ref> eGFR ¼ 133 Â min(ScysC/0.8,1)</s><s>À0.499 Â max(ScysC/0.8,1)</s><s>À1.328 Â 0.996 Age Â (0.932 if female) Combined equations CKD-EPI crea,cysc <ref type="bibr" target="#b2">[4]</ref> eGFR ¼ 135 Â min(Scr/j,1) a Â max(Scr/j,1) À0.601 Â min(ScysC/0.8,1)</s><s>À0.375 Â max(ScysC/0.8,1)</s><s>À0.711 Â 0.995 Age Â (0.969 if female) (j ¼ 0.7 for females, 0.9 for males, a ¼ À0.248 for females and À0.207 for males) BIS2 <ref type="bibr" target="#b6">[8]</ref> eGFR ¼ 767 Â ScysC À0.61 Â Scr À0.40 Â Age À0.57</s><s>Â (0.87 if female)</s></p><formula xml:id="formula_5">Q cysC ¼ 0.01704 Â Age -0.3384 ¼ 0.863 þ 0.01704 Â (Age -70) (R 2 ¼ 0.919; see Figure</formula><p><s>Scr, serum creatinine (mg/dL); ScysC, serum cystatin C (mg/L); Ht, height in cm.</s></p><formula xml:id="formula_6">| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Therefore,</formula><p><s>we defined the Q cysC normalization factor for cystatin C as 0.82 mg/L until the age of 70 years and then Q cysC gradually (and linearly) increases (Figure <ref type="figure" target="#fig_2">1</ref>).</s><s>The mode of the ScysC distribution (Figure <ref type="figure" target="#fig_3">2</ref>) of the n ¼ 1333 apparently healthy subjects was 0.95 mg/L.</s><s>Based on this analysis, and for the sake of simplicity, we fixed Q cysC to 0.82 mg/L for all ages &lt;70 years and to 0.95 mg/L for older ages.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Performance results of the different equations</head><p><s>The performance statistics for the three FAS equations for the different age groups are presented in Tables <ref type="table" target="#tab_7">6-8</ref>.</s><s>The    adults and older adults.</s><s>The total RMSE for all n ¼ 6132 measurements is also shown.</s><s>For children the FAS cysC equation has smaller RMSE than the FAS crea equation.</s><s>For adults there is a slightly smaller RMSE for the single biomarker FAS crea equation compared with the single marker FAS cysC equation.</s><s>For older adults there is no real preference for the value of a.</s><s>For all age groups the RMSE is minimal for a % 0.5 (¼ combined FAS equation).</s><s>Tables <ref type="table" target="#tab_7">6-8</ref> are presented for all subjects within each age group, but also for subgroups according to the mGFR threshold of 60 mL/min/1.73</s><s>m 2 .</s><s>For children, the FAS cysC equation performs significantly better than the FAS crea equation based on Q crea (age) and slightly better than or, in some cases, equivalent to the FAS crea equation based on Q crea (height) (Table <ref type="table" target="#tab_4">6</ref>).</s><s>We found that n ¼ 7 children [for Q crea (height)] and n ¼ 20 children [for Q crea (age)] with Scr/Q crea &lt;0.67 had FAS crea predictions that largely overestimate mGFR and were responsible for the large bias, RMSE and worse performance statistics.</s><s>These children had spina bifida, Duchenne muscular dystrophy and severe growth retardation, explaining the very low Scr values and the poor match between Q crea and age.</s><s>The FAS cysC equation has equivalent Lin's CCC with CAPA but better RMSE.</s><s>Also, P10 and P30 performance statistics were superior to CAPA.</s><s>The Schwartz cysC equation shows the best performance in the mGFR &lt;60 mL/min/1.73</s><s>m 2 subgroup.</s><s>However, although all children suffered from some underlying renal pathology, this subgroup was rather small (n ¼ 57, 15%).</s><s>The FAS combi equations [based on Q crea (age) and Q crea (height)] outperform all other paediatric equations and increase the precision for P10 to %45% and P30 to %90%, which is significantly higher (P &lt; 0.0001) compared with single biomarker equations, including the single biomarker FAS equations.</s></p><formula xml:id="formula_7">| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | F u l l -a g e -s p e c t r u m c y s t a t i n C -b a s d e G F R e q u a t i o n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |</formula><p><s>For adults, the FAS cysC equation performs worse than FAS crea , but better (overall and in the mGFR !60 mL/min/1.73</s><s>m 2 subgroup) or equivalent (in the mGFR &lt;60 mL/min/1.73</s><s>m 2 subgroup) than the CKD-EPI cysC equation.</s><s>The FAS cysC equation is significantly better than the CAPA equation.</s><s>The combined equations show higher precision, but the difference with the FAS crea equation is small.</s><s>However, the FAS combi equation is overall the best prediction equation and performs better than the CKD-EPI combined equation, except for mGFR &lt;60 mL/min/1.73</s><s>m 2 , where the performance is statistically equivalent.</s></p><p><s>In older adults, the FAS cysC equation (with Q cysC ¼ 0.95) performs better than the CKD-EPI cysC equation and shows equivalent performance with the FAS crea equation.</s><s>If we use the linear function Q cysC ¼ 0.863 þ 0.01704 Â (Age -70) to normalize ScysC in the FAS cysC and FAS combi equations, then the performance results (data not shown) are not significantly different than when Q cysC ¼ 0.95 is used to normalize ScysC in the FAS equation.</s><s>The combined FAS equation is performing equivalent to the BIS2 equation, reaching P10 &gt; 50% and P30 &gt; 90%, and better than the combined CKD-EPI equation.</s></p><p><s>In Tables <ref type="table" target="#tab_7">6-8</ref>, we highlighted (the equations marked with asterisk) the best performing equation per biomarker category CKD-EPI combi * eGFR -mGFR 7.0 (6.2; 7.9) 5.9 (5.0; 6.9) 6.9 (6.1; 7.8) 4.9 (3.9; 5.9) Asterisks indicate the best performing equation(s) <ref type="bibr" target="#b11">[13]</ref> within the same biomarker category, across all performance statistics.</s><s>The bold values are the best result(s) for each performance statistic, across all equations.</s><s>FAS, full-age-spectrum eGFR equation (Scr-based with Q ¼ 0.70 mg/dL for females and Q ¼ 0.90 mg/dL for males; SCysC-based with Q 0 ¼ 0.82 mg/L).</s><s>FAS combi is calculated for a ¼ 0.5.</s></p><p><s>u l l -a g e -s p e c t r u m c y s t a t i n C -b a s e d e G F R e q u a t i o n</s></p><formula xml:id="formula_8">| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |</formula><p><s>based on the scoring system previously used by Hoste et al. <ref type="bibr" target="#b11">[13]</ref>, which is based on bias, P10 and P30.</s><s>We also highlighted (in bold) the best performance statistic.</s><s>We also calculated the performance statistics (RMSE in Figure <ref type="figure" target="#fig_3">2</ref> and P30 in Figure <ref type="figure" target="#fig_5">3</ref>) of the FAS combi equation as a function of the weighting parameter a.</s><s>These figures show the performance statistics as a continuous function of a, evolving from the FAS cysC equation (with a ¼ 0) to the FAS crea equation (with a ¼ 1), and in-between for the FAS combi for all values of a.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>D I S C U S S I O N</head><p><s>Through the introduction of the international certified reference material ERM-DA471/IFCC for cystatin C <ref type="bibr" target="#b3">[5]</ref> it has become possible to develop ScysC-based as well as combined Scr-/ScysC-based eGFR equations on the basis of normalized biomarkers.</s><s>Despite the fact that manufacturers still need to improve the accuracy of cystatin C assays <ref type="bibr" target="#b17">[19]</ref>, we have shown here that the basic concept upon which the FAS crea equation was built <ref type="bibr" target="#b0">[2]</ref> is not only applicable for normalized Scr, but can also be applied to normalized ScysC.</s><s>By replacing normalized Scr with ScysC, or introducing the (weighted) average of both biomarkers, we can change from a Scr-based FAS equation to a ScysC-based FAS equation or a combined Scr-/ScysC-based FAS equation.</s><s>These FAS equations show performance values that are equivalent or in some conditions superior to the currently recommended eGFR equations for children, adolescents, adults and older adults.</s><s>Normalization of the biomarkers is a key in this construction.</s><s>In the case of Scr, normalization is required to account for the difference in creatinine generation during childhood, the age/gender differences during adolescence and the difference between adult men and women.</s><s>Normalization of ScysC is required to account for the age effect beyond the age of 70 years.</s><s>For the healthy population, the normalized biomarkers show equivalent distributions with mean of '1' and 2.5th and 97.5th Pct of 0.67 and 1.33, respectively.</s><s>These similar characteristics of normalized biomarker concentration distributions lead to an interchangeable usage of both renal markers in the FAS equation(s).</s></p><p><s>The performance of the new FAS cysC equation was better than the CAPA equation and better (in adults with mGFR !60 mL/min/1.73</s><s>m 2 and in older adults) or equivalent (in adults with mGFR &lt;60 mL/min/1.73</s><s>m 2 ) to the CKD-EPI cysC equation.</s><s>In children, the RMSE statistic is worst (highest) for the FAS crea equation due to a fraction of children with Scr/ Q crea &lt;0.67.</s><s>Therefore, we would recommend not to use FAS crea (or the combined FAS equations) when Scr/Q crea &lt;0.67 <ref type="bibr" target="#b0">[2]</ref>.</s><s>For adults, based on the performance statistics (RMSE and P30), there is still a slight preference for the single biomarker FAS crea equation over the single biomarker FAS cysC equation.</s><s>For older adults, both single biomarker FAS equations perform in a similar manner.</s><s>However, for all age groups, the FAS combi equation with a % 0.5 (corresponding to the average of both biomarkers) showed the smallest RMSE and the highest P30 and P10.</s><s>Also the FAS combi equation outperformed all other combined equations, with the exception of the BIS2 equation, which showed an equivalent performance for older adults (but note that BIS data used to derive the BIS equations are part of the current validation dataset) and the CKD-EPI equation for adults with mGFR &lt;60 mL/min/1.73</s><s>m 2 , where FAS showed equivalent performance results.</s></p><p><s>When the overall performance statistics for specific age groups was calculated, we found that a % 0.5 corresponding to the average of normalized creatinine and cystatin C biomarker concentrations gave the best performance statistics for all age groups and demonstrated the smallest RMSE and highest P10 and P30 values.</s><s>Although we calculated the average of both biomarkers and entered this into the FAS equation, it approximated the average of both single biomarker FAS equations (Scr and ScysC), a finding that has been observed by Bjo ¨rk et al. <ref type="bibr" target="#b18">[20,</ref><ref type="bibr" target="#b19">21]</ref> in a Swedish cohort, when combining the Scr-based Lund-Malmo ¨and the ScysC-based CAPA equation.</s><s>The choice to use a single or the mean of two biomarkers should be based on the clinical context, when conditions are disclosed that invalidate either Scr or ScysC as renal biomarker.</s><s>The use of Scr may be discouraged in case of severe muscle wasting (anorexic patients, patients with muscle disorder, like Duchenne muscle dystrophy), immobile patients, or elderly cachectic patients with reduced muscle mass.</s><s>Also, abnormal meat consumption, abnormal muscle development in athletes or weight lifters, or medication usage that affects creatinine generation may have an impact on the validity of creatinine as a renal biomarker.</s><s>The use of ScysC-based equations may be discouraged when patients are treated with (high dose) glucocorticoids or other medication impacting on the biomarker's serum concentration <ref type="bibr" target="#b20">[22]</ref>, in obese patients, tobacco users or patients with thyroid dysfunction or inflammation <ref type="bibr" target="#b9">[11,</ref><ref type="bibr" target="#b21">[23]</ref><ref type="bibr" target="#b22">[24]</ref><ref type="bibr" target="#b23">[25]</ref>.</s><s>The combination of both biomarkers has the advantage that it may cancel out the non-GFRrelated factors influencing creatinine and cystatin C in different directions compared with mGFR <ref type="bibr" target="#b22">[24]</ref><ref type="bibr" target="#b23">[25]</ref><ref type="bibr" target="#b24">[26]</ref>.</s><s>The great advantage of our approach is that the same equation can be used, only the appropriate normalized biomarker has to be chosen (either Scr/Q crea , or ScysC/Q cysC or the average of both).</s><s>However, the cost of cystatin C is relatively high and additional studies are needed to prove that measuring cystatin C is cost-effective.</s><s>In the context of GFR estimation, the additional value of cystatin C could be defined by the clinical condition, knowing that non-GFR determinants influence both creatinine and cystatin C.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Siemens N-LatexV R PENIA [8] Yes BN Prospec 1.5, 3.5, 2.4 at 0.8, 2.3, 7.4 mg/L Kent, 2008-11 Siemens PENIA [12] No, recalculation by MF ¼ 1.11 BN Prospec analyser 3.5 at 2.3 mg/L Paris, 2013 Siemens PENIA Yes Dimension Vista 3.5 CRIC [9], 2003-08 Siemens N-LatexV R PENIA [4] No, recalculation by authors ¼ 1.12 Â (0.083 þ 0.789 Â (0.039 þ 1.061 Â CRIC cysC ) BN Prospec analyser 4.9 MF, multiplication factor; CV, coefficient of variation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 1 :</head><label>1</label><figDesc><div><p><s>FIGURE 1: (a) The linear relationship between median (solid black circles) ScysC and age for the n ¼ 1333 apparently healthy Berlin Initiative Study participants (grey circles).</s><s>(b) Histogram for ScysC measurements of n ¼ 1333 apparently healthy older adults.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 2 :</head><label>2</label><figDesc><div><p><s>FIGURE 2: RMSE as a function of the weighting factor a for children [based on Q(height)],adults and older adults.</s><s>The total RMSE for all n ¼ 6132 measurements is also shown.</s><s>For children the FAS cysC equation has smaller RMSE than the FAS crea equation.</s><s>For adults there is a slightly smaller RMSE for the single biomarker FAS crea equation compared with the single marker FAS cysC equation.</s><s>For older adults there is no real preference for the value of a.</s><s>For all age groups the RMSE is minimal for a % 0.5 (¼ combined FAS equation).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>FAS(Ht), FAS equation based on Q(height); Schwartz, Schwartz equation for children (Scr-based ¼ 0.413 Ht/Scr; cystatin C-based ¼ 70.1 ScysC À| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |FAS crea equation [for children in two versions, based on Q crea (age) and Q crea (height)] is compared with the relevant Scr-based recommended equations (Schwartz for children, CKD-EPI for adults, BIS1 for older adults).</s><s>The FAS cysC equation is compared with the ScysC-based Schwartz equation (for children), the CAPA equation (for all ages) and ScysC-based CKD-EPI equation (for adults).</s><s>Finally, the FAS combi equation is compared with the combined CKD-EPI equation (for adults and older adults) and the combined BIS2 equation for older adults.</s><s>To our knowledge, there is no combined equation for children available yet (based on the certified reference material).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>FIGURE 3 :</head><label>3</label><figDesc><div><p><s>FIGURE 3: P30 as a function of the weighting factor a for the different age groups.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Overview of the methods used in this study for mGFR and Scr</s></p></div></figDesc><table><row><cell>Origin</cell><cell>mGFR</cell><cell>Scr</cell></row><row><cell>Leuven, Belgium</cell><cell>51 Cr-EDTA (4 points)</cell><cell>Creatinine Plus, Roche enzym.</cell></row><row><cell>Lyon, France</cell><cell>Inulin a or Iohexol (3 points)</cell><cell>Creatinine Plus, Roche enzym.</cell></row><row><cell>Saint-Etienne, France</cell><cell>Iohexol (2 points)</cell><cell>Enzymatic, Orthoclinical Diagn.</cell></row><row><cell>Tromsø, Norway</cell><cell>Iohexol (1 point)</cell><cell>Creatinine Plus, Roche enzym.</cell></row><row><cell>Rochester, MN, USA</cell><cell>Iothalamate a</cell><cell>Creatinine Plus, Roche enzym.</cell></row><row><cell>Berlin, Germany</cell><cell>Iohexol (8 points)</cell><cell>Creatinine Plus, Roche enzym.</cell></row><row><cell>Kent, UK</cell><cell>Iohexol (3 points)</cell><cell>IDMS</cell></row><row><cell>Paris, France</cell><cell>51 Cr-EDTA a</cell><cell>Enzymatic, Siemens, standardized to IDMS</cell></row><row><cell>CRIC, USA</cell><cell>125 I-Iothalamate a</cell><cell>calculated back to Creatinine Plus, Roche enzym.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Overview of the methods for ScysC</s></p></div></figDesc><table><row><cell>Origin, time of</cell><cell>ScysC assay</cell><cell>Calibration to reference</cell><cell>Automate</cell><cell>CV (%)</cell></row><row><cell>measurement</cell><cell></cell><cell>(ERMV R -DA471/IFCC)</cell><cell></cell><cell></cell></row><row><cell>Leuven, 2015</cell><cell>Roche PETIA (Tina quantV R Gen2)</cell><cell>Yes</cell><cell>Integra 400 Plus</cell><cell>2.6, 1.2, 1.0 at 0.503, 2.98, 6.11 mg/L</cell></row><row><cell>Lyon, 2010-15</cell><cell>Siemens N-LatexV R PENIA</cell><cell>No, recalculation by MF ¼ 1.11</cell><cell>BN Prospec</cell><cell>3.5 at 2.3 mg/L</cell></row><row><cell></cell><cell></cell><cell>before April 2011; yes after</cell><cell>analyser</cell><cell></cell></row><row><cell></cell><cell></cell><cell>April 2011</cell><cell></cell><cell></cell></row></table><note><p><s>[13]t-Etienne, 2012 Siemens PENIA[13]Yes BN Prospec analyser 2.9, 2.1 at 1.03, 1.93 mg/LTromsø, 2007-08 Roche PETIA [14] (Tina quantV R Gen1) No, recalculation using À0.064 þ ScysC Â 0.998 Gentian reagents, Modular P800 analyser 3.2 Rochester, 2001-11 Siemens PENIA [11] No, recalculation by MF ¼ 1.14 Dade Behring BN II Nephelometer</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Patient characteristics in the different cohorts from young age to old age (mean 6 SD) (in years) , number of patients; mGFR, measured glomerular filtration rate (mL/min/1.73</s><s>m 2 ); Scr, serum creatinine (mg/dL); ScysC, serum cystatin C (mg/L).</s></p></div></figDesc><table><row><cell>Data origin</cell><cell>n</cell><cell>Age</cell><cell>mGFR</cell><cell>Scr</cell><cell>ScysC</cell></row><row><cell>Leuven (Belgium)</cell><cell>114</cell><cell>8.8 6 5.5</cell><cell>89.2 6 21.5</cell><cell>0.58 6 0.36</cell><cell>1.00 6 0.35</cell></row><row><cell>Lyon (France)</cell><cell>259</cell><cell>11.1 6 3.6</cell><cell>88.8 6 33.5</cell><cell>0.68 6 0.30</cell><cell>1.22 6 0.43</cell></row><row><cell>Saint-Etienne (France)</cell><cell>203</cell><cell>48.7 6 10.3</cell><cell>94.7 6 24.4</cell><cell>0.87 6 0.19</cell><cell>0.90 6 0.26</cell></row><row><cell>Paris (France)</cell><cell>603</cell><cell>50.3 6 13.1</cell><cell>67.1 6 27.2</cell><cell>1.29 6 0.74</cell><cell>1.41 6 0.81</cell></row><row><cell>Lyon (France)</cell><cell>598</cell><cell>54.6 6 13.7</cell><cell>74.9 6 30.9</cell><cell>1.13 6 0.57</cell><cell>1.24 6 0.58</cell></row><row><cell>CRIC (USA)</cell><cell>674</cell><cell>56.9 6 12.5</cell><cell>50.7 6 21.8</cell><cell>1.60 6 0.50</cell><cell>1.43 6 0.51</cell></row><row><cell>Tromsø (Norway)</cell><cell>1627</cell><cell>58.1 6 3.8</cell><cell>91.7 6 14.4</cell><cell>0.76 6 0.14</cell><cell>0.73 6 0.12</cell></row><row><cell>Rochester CKD (USA)</cell><cell>687</cell><cell>64.8 6 8.8</cell><cell>80.4 6 21.3</cell><cell>0.85 6 0.23</cell><cell>0.87 6 0.24</cell></row><row><cell>Rochester KFC (USA)</cell><cell>406</cell><cell>65.9 6 9.2</cell><cell>79.5 6 20.7</cell><cell>0.84 6 0.18</cell><cell>0.83 6 0.18</cell></row><row><cell>Berlin (Germany)</cell><cell>567</cell><cell>78.5 6 6.2</cell><cell>60.3 6 16.4</cell><cell>0.99 6 0.37</cell><cell>1.14 6 0.38</cell></row><row><cell>Kent (UK)</cell><cell>394</cell><cell>80.4 6 4.6</cell><cell>51.5 6 18.8</cell><cell>1.30 6 0.66</cell><cell>1.45 6 0.61</cell></row><row><cell>Total</cell><cell>6132</cell><cell>58.2 6 17.6</cell><cell>75.5 6 26.5</cell><cell>1.01 6 0.51</cell><cell>1.06 6 0.52</cell></row></table><note><p><s>n</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Patient characteristics in the different age groups (mean 6 SD)</s></p></div></figDesc><table><row><cell>Group</cell><cell>n</cell><cell>No. of males</cell><cell>No. of females</cell><cell>mGFR</cell><cell>Scr</cell><cell>ScysC</cell></row><row><cell>Children 18 years</cell><cell>368</cell><cell>193</cell><cell>175</cell><cell>89.2 6 30.4</cell><cell>0.65 6 0.31</cell><cell>1.15 6 0.42</cell></row><row><cell>Adults 18-70 years</cell><cell>4295</cell><cell>2301</cell><cell>1994</cell><cell>80.2 6 25.6</cell><cell>1.00 6 0.50</cell><cell>0.99 6 0.51</cell></row><row><cell>Older adults !70 years</cell><cell>1469</cell><cell>771</cell><cell>698</cell><cell>58.5 6 20.0</cell><cell>1.13 6 0.52</cell><cell>1.24 6 0.51</cell></row><row><cell>Total</cell><cell>6132</cell><cell>3265</cell><cell>2867</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>n, number of patients; mGFR, measured glomerular filtration rate (mL/min/1.73</s><s>m 2 ); Scr, serum creatinine (mg/dL); ScysC, serum cystatin C (mg/L).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 6 .</head><label>6</label><figDesc><div><p><s>Children n ¼ 368 (age 18 years)</s></p></div></figDesc><table><row><cell>Combined Scr-/ScysC-based eGFR</cell><cell>FAS combi * FAS combi (Ht)*</cell><cell>0.9 (À0.9; 2.7) À2.2 (À4.0; À0.4)</cell><cell>1.05 (1.03; 1.07) 1.01 (0.99; 1.03)</cell><cell>17.5 (15.1; 19.7) 17.6 (15.5; 19.7)</cell><cell>0.81 (0.77; 0.84) 0.80 (0.77; 0.84)</cell><cell>44.6 (39.5; 49.7) 43.2 (38.1; 48.3)</cell><cell>90.8 (87.8; 93.7) 92.1 (89.4; 94.9)</cell><cell></cell><cell>FAS combi FAS combi (Ht)*</cell><cell>8.3 (6.2; 10.5) 5.0 (2.9; 7.1)</cell><cell>1.21 (1.15; 1.27) 1.14 (1.08; 1.20)</cell><cell>11.6 (9.4; 13.5) 9.3 (7.3; 11.0)</cell><cell>0.56 (0.41; 0.69) 0.65 (0.49; 0.77)</cell><cell>28.1 (16.0; 40.1) 38.6 (25.6; 51.6)</cell><cell>71.9 (59.9; 84.0) 80.7 (70.1; 91.3)</cell><cell></cell><cell>FAS combi * FAS combi (Ht)*</cell><cell>À0.5 (À2.5; 1.6) À3.5 (À5.6; À1.4)</cell><cell>1.01 (0.99; 1.03) 0.98 (0.96; 1.00)</cell><cell>18.4 (13.5; 20.8) 18.8 (16.3; 21.0)</cell><cell>0.71 (0.65; 0.76) 0.69 (0.62; 0.74)</cell><cell>47.6 (42.0; 53.2) 44.1 (38.5; 49.6)</cell><cell>94.2 (91.6; 96.8) 94.2 (91.6; 96.8)</cell></row><row><cell></cell><cell>Schwartz cysC</cell><cell>À21.6 (À23.7; À19.6)</cell><cell>0.79 (0.78; 0.81)</cell><cell>29.6 (27.0; 32.1)</cell><cell>0.49 (0.44; 0.54)</cell><cell>16.0 (12.3; 19.8)</cell><cell>68.8 (64.4; 73.5)</cell><cell></cell><cell>Schwartz cysC *</cell><cell>À2.4 (À5.0; 0.2)</cell><cell>0.98 (0.91; 1.04)</cell><cell>10.0 (7.5; 12.0)</cell><cell>0.55 (0.35; 0.71)</cell><cell>36.8 (23.9; 49.8)</cell><cell>86.0 (76.7; 95.3)</cell><cell></cell><cell>Schwartz cysC</cell><cell>À25.2 (À27.4; À23.0)</cell><cell>0.76 (0.74; 0.78)</cell><cell>32.0 (29.1; 34.5)</cell><cell>0.33 (0.27; 0.38)</cell><cell>12.2 (8.6; 15.9)</cell><cell>65.6 (60.3; 70.9)</cell></row><row><cell></cell><cell>CAPA</cell><cell>0.3 (À2.0; 2.6)</cell><cell>1.03 (1.00; 1.05)</cell><cell></cell><cell>0.74 (0.68; 0.78)</cell><cell>36.4 (31.5; 41.4)</cell><cell>76.6 (72.3; 81.0)</cell><cell></cell><cell>CAPA</cell><cell>3.3 (À0.4; 7.1)</cell><cell></cell><cell></cell><cell>0.47 (0.28; 0.63)</cell><cell>29.8 (17.6; 42.1)</cell><cell>66.7 (54.0; 79.3)</cell><cell></cell><cell>CAPA</cell><cell>À0.2 (À2.9; 2.4)</cell><cell>1.02 (0.99; 1.04)</cell><cell></cell><cell>0.60 (0.52; 0.66)</cell><cell>37.6 (32.2; 43.0)</cell><cell>78.5 (73.9; 83.1)</cell></row><row><cell>ScysC-based eGFR</cell><cell>FAS cysC *</cell><cell></cell><cell></cell><cell></cell><cell>0.73 (0.68; 0.77)</cell><cell>40.5 (35.5; 45.5)</cell><cell>86.1 (82.6; 89.7)</cell><cell></cell><cell>FAS cysC</cell><cell></cell><cell></cell><cell></cell><cell>0.48 (0.29; 0.64)</cell><cell>24.6 (13.0; 36.1)</cell><cell>68.4 (56.0; 80.9)</cell><cell></cell><cell>FAS cysC *</cell><cell>À7.2 (À9.5; À5.0)</cell><cell></cell><cell></cell><cell>0.59 (0.52; 0.65)</cell><cell>43.4 (37.9; 48.9)</cell><cell>89.4 (85.9; 92.8)</cell></row><row><cell></cell><cell>Schwartz crea</cell><cell></cell><cell></cell><cell></cell><cell>0.63 (0.57; 0.68)</cell><cell>40.5 (35.5; 45.5)</cell><cell>79.9 (75.8; 84.0)</cell><cell></cell><cell>Schwartz crea</cell><cell></cell><cell></cell><cell></cell><cell>0.55 (0.40; 0.68)</cell><cell>36.8 (23.9; 49.8)</cell><cell>71.9 (59.9; 84.0)</cell><cell></cell><cell>Schwartz crea</cell><cell>11.5 (8.0; 15.1)</cell><cell></cell><cell></cell><cell>0.48 (0.40; 0.55)</cell><cell>41.2 (35.7; 46.7)</cell><cell>81.4 (77.0; 85.7)</cell></row><row><cell></cell><cell>FAS crea (Ht)*</cell><cell></cell><cell></cell><cell></cell><cell>0.65 (0.59; 0.70)</cell><cell>42.7 (37.6; 47.7)</cell><cell>84.5 (80.8; 88.2)</cell><cell></cell><cell>FAS crea (Ht)*</cell><cell></cell><cell></cell><cell></cell><cell>0.66 (0.50; 0.77)</cell><cell>45.6 (32.3; 58.9)</cell><cell>71.9 (59.9; 84.0)</cell><cell></cell><cell>FAS crea (Ht)*</cell><cell>3.5 (0.1; 6.9)</cell><cell></cell><cell></cell><cell>0.50 (0.41; 0.57)</cell><cell>42.1 (36.6; 47.6)</cell><cell>86.8 (83.0; 90.6)</cell></row><row><cell>Scr-based eGFR</cell><cell>FAS crea</cell><cell>12.3 (7.7; 17.0)</cell><cell>1.17 (1.12; 1.21)</cell><cell>47.0 (27.2; 67.6)</cell><cell>0.43 (0.36; 0.49)</cell><cell>32.3 (27.5; 37.1)</cell><cell>78.3 (74.0; 82.5)</cell><cell>(n ¼ 57)</cell><cell>FAS crea</cell><cell>12.5 (10.0; 15.1)</cell><cell>1.31 (1.24; 1.37)</cell><cell>15.8 (12.7; 18.4)</cell><cell>0.44 (0.29; 0.56)</cell><cell>10.5 (2.3; 18.7)</cell><cell>63.2 (50.2; 76.1)</cell><cell>(n ¼ 311)</cell><cell>FAS crea</cell><cell>12.3 (6.8; 17.8)</cell><cell>1.14 (1.09; 1.19)</cell><cell>50.7 (10.5; 77.5)</cell><cell>0.29 (0.22; 0.37)</cell><cell>36.3 (31.0; 41.7)</cell><cell>81.0 (76.6; 85.4)</cell></row><row><cell></cell><cell>mGFR ¼ 89.2 (n ¼ 368)</cell><cell>eGFR -mGFR</cell><cell>eGFR/mGFR</cell><cell>RMSE</cell><cell>Lin's CCC</cell><cell>P10 (%)</cell><cell>P30 (%)</cell><cell>mGFR &lt;60 mL/min/1.73 m 2</cell><cell>mGFR ¼ 45.2</cell><cell>eGFR -mGFR</cell><cell>eGFR/mGFR</cell><cell>RMSE</cell><cell>Lin's CCC</cell><cell>P10 (%)</cell><cell>P30 (%)</cell><cell>mGFR !60 mL/min/1.73 m 2</cell><cell>mGFR ¼ 97.3</cell><cell>eGFR -mGFR</cell><cell>eGFR/mGFR</cell><cell>RMSE</cell><cell>Lin's CCC</cell><cell>P10 (%)</cell><cell>P30 (%)</cell></row></table><note><p><s>[13](0.9; 6.6) 11.1 (8.1; 14.1) À5.1 (À7.2;À3.1)1.06 (1.04; 1.09) 1.15 (1.12; 1.18) 0.98 (0.96; 1.01) 28.3 (11.4; 39.2) 31.3 (13.9; 42.9) 20.4 (17.9; 22.5) 22.3 (20.0; 24.3) 5.1 (3.0; 7.2) 8.8 (6.5; 11.0) 6.2 (3.1; 9.3) 1.14 (1.08; 1.20) 1.22 (1.16; 1.29) 1.17 (1.09; 1.25) 1.10 (1.01; 1.19) 9.4 (7.5; 10.9) 12.2 (9.7; 14.2) 13.1 (9.8; 15.7) 14.3 (10.4; 17.3) 1.05 (1.02; 1.08) 1.13 (1.10; 1.17) 0.95 (0.93; 0.97) 30.5 (10.1; 42.0) 33.7 (12.7; 45.9) 21.5 (18.8; 23.8) 23.5 (21.0; 25.8)Asterisks indicate the best performing equation(s)[13]within the same biomarker category, across all performance statistics.</s><s>The bold values are the best result(s) for each performance statistic, across all equations.</s><s>FAS, full-age-spectrum eGFR equation, based on Q(age);</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 7 .</head><label>7</label><figDesc><div><p><s>Adults n ¼ 4295 (age 18-70 years)</s></p></div></figDesc><table><row><cell></cell><cell>Scr-based eGFR</cell><cell></cell><cell cols="2">ScysC-based eGFR</cell><cell></cell><cell cols="2">Combined Scr-/ScysC-based eGFR</cell></row><row><cell cols="2">mGFR ¼ 80.1 (n ¼ 4295) FAS crea *</cell><cell>CKD-EPI crea *</cell><cell>FAS cysC *</cell><cell>CKD-EPI cysC</cell><cell>CAPA</cell><cell>FAS combi *</cell><cell>CKD-EPI combi</cell></row><row><cell>eGFR -mGFR</cell><cell>1.4 (0.9; 1.9)</cell><cell>2.4 (1.9; 2.8)</cell><cell>4.2 (3.7; 4.8)</cell><cell>8.0 (7.6; 8.5)</cell><cell>8.9 (8.3; 9.5)</cell><cell>1.9 (1.5; 2.4)</cell><cell>6.2 (5.8; 6.6)</cell></row><row><cell>eGFR/mGFR</cell><cell cols="7">1.05 (1.04; 1.06) 1.06 (1.05; 1.07) 1.08 (1.07; 1.09) 1.11 (1.10; 1.12) 1.12 (1.11; 1.13) 1.05 (1.04; 1.06) 1.09 (1.08; 1.10)</cell></row><row><cell>RMSE</cell><cell cols="7">16.0 (15.4; 16.6) 15.1 (14.6; 15.6) 17.7 (17.2; 18.2) 18.1 (17.6; 18.5) 21.3 (20.8; 21.8) 14.1 (13.6; 14.6) 15.3 (14.9; 15.8)</cell></row><row><cell>Lin's CCC</cell><cell cols="7">0.80 (0.79; 0.81) 0.82 (0.81; 0.83) 0.78 (0.76; 0.79) 0.78 (0.77; 0.80) 0.73 (0.72; 0.74) 0.84 (0.83; 0.85) 0.83 (0.82; 0.84)</cell></row><row><cell>P10 (%)</cell><cell cols="7">43.6 (42.1; 45.1) 46.0 (44.5; 47.5) 37.6 (36.2; 39.1) 32.5 (31.1; 34.0) 31.5 (30.1; 32.9) 47.3 (45.8; 48.8) 41.0 (39.6; 42.5)</cell></row><row><cell>P30 (%)</cell><cell cols="7">87.6 (86.6; 88.6) 88.1 (87.1; 89.0) 82.6 (81.4; 83.7) 80.4 (79.3; 81.6) 75.6 (74.3; 76.9) 89.9 (89.0; 90.8) 88.2 (87.2; 89.1)</cell></row><row><cell cols="2">mGFR &lt;60 mL/min/1.73 m 2 (n ¼ 925)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>mGFR ¼ 42.0</cell><cell>FAS crea *</cell><cell>CKD-EPI crea *</cell><cell>FAS cysC</cell><cell>CKD-EPI cysC *</cell><cell>CAPA</cell><cell>FAS combi</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc><div><p><s>Lin's CCC 0.54 (0.50; 0.57) 0.55 (0.51; 0.58) 0.56 (0.52; 0.60) 0.57 (0.53; 0.60) 0.57 (0.53; 0.60) 0.61 (0.58; 0.65) 0.62 (0.58; 0.65) P10 (%) 31.5 (28.5; 34.5) 31.7 (28.7; 34.7) 27.9 (25.0; 30.8) 29.0 (26.0; 31.9)</s><s>28.5 (25.6; 31.5)</s><s>33.8 (30.8; 36.9)</s><s>34.4 (31.3; 37.4) P30 (%) 70.8 (67.9; 73.7) 72.3 (69.4; 75.2) 68.0 (65.0; 71.0) 70.5 (67.5; 73.4) 70.9 (68.0; 73.9) 75.2 (72.5; 78.0) 79.0 (76.4; 81.7)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>5.3 (4.3; 6.2)</cell><cell>6.3 (5.5; 7.0)</cell><cell>4.2 (3.4; 5.1)</cell></row><row><cell cols="2">eGFR/mGFR 1.20 (1.mGFR !60 mL/min/1.73 m 2 (n ¼ 3370)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>mGFR ¼ 90.6</cell><cell>FAS crea *</cell><cell>CKD-EPI crea *</cell><cell>FAS cysC *</cell><cell>CKD-EPI cysC</cell><cell>CAPA</cell><cell>FAS combi *</cell><cell>CKD-EPI combi</cell></row><row><cell>eGFR -mGFR</cell><cell cols="2">À0.1 (À0.7; 0.4) 1.4 (0.9; 1.9)</cell><cell>3.5 (2.9; 4.1)</cell><cell>8.9 (8.4; 9.5)</cell><cell>9.9 (9.2; 10.6)</cell><cell>0.8 (0.3; 1.2)</cell><cell>6.7 (6.3; 7.2)</cell></row><row><cell>eGFR/mGFR</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>19; 1.23) 1.16(1.13;1.18)1.19(1.17;1.22)</s><s>1.11 (1.09; 1.14) 1.12 (1.10; 1.15) 1.18 (1.16; 1.20) 1.10 (1.08; 1.12) RMSE 15.4 (14.0; 16.6) 16.1 (14.8; 17.2) 14.8 (13.7; 15.8) 16.2 (14.9; 17.5) 16.0 (14.7; 17.3) 13.2 (12.1; 14.2) 14.4 (13.1; 15.6) 1.01 (1.00; 1.01) 1.03 (1.03; 1.04) 1.05 (1.04; 1.06) 1.11 (1.11; 1.12) 1.12 (1.11; 1.13) 1.02 (1.01; 1.02) 1.09 (1.08; 1.09) RMSE 16.2 (15.5; 16.8) 14.8 (14.2; 15.3) 18.4 (17.8; 18.9) 18.6 (18.1; 19.0) 22.5 (21.9; 23.1) 14.3 (13.8; 14.9) 15.6 (15.1; 16.0) Lin's CCC 0.59 (0.57; 0.61) 0.57 (0.54; 0.59) 0.51 (0.49; 0.54) 0.48 (0.46; 0.50) 0.42 (0.40; 0.45) 0.64 (0.62; 0.66) 0.58 (0.56; 0.60) P10 (%) 47.0 (45.3; 48.7) 49.9 (48.2; 51.6) 40.3 (38.6; 41.9) 33.5 (31.9; 35.1) 32.3 (30.7; 33.9) 50.9 (49.3; 52.6) 42.9 (41.2; 44.6) P30 (%) 92.2 (91.3; 93.1) 92.4 (91.5; 93.3) 86.6 (85.4; 87.7) 83.2 (91.9; 84.4) 76.9 (75.4; 78.3) 93.9 (93.1; 94.8) 90.7 (89.7; 91.7)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 8 .</head><label>8</label><figDesc><div><p><s>[13]r people nAsterisks indicate the best performing equation(s)[13]within the same biomarker category, across all performance statistics.</s><s>The bold values are the best result(s) for each performance statistic, across all equations.</s><s>FAS, full-age-spectrum eGFR</s></p></div></figDesc><table><row><cell>¼ 1469 (age !70 years)</cell><cell>Scr-based eGFR ScysC-based eGFR Combined Scr-/ScysC-based eGFR</cell><cell>CKD-EPI combi BIS2* mGFR ¼ 58.5 (n ¼ 1469) FAS crea * CKD-EPI crea BIS1* FAS cysC * CKD-EPI cysC CAPA FAS combi *</cell><cell>4.5 (4.0; 5.1) À1.2 (À1.7; À0.7) eGFR -mGFR À2.6 (À3.2; À2.0) 4.6 (4.0; 5.3) À2.9 (À3.5; À2.4) 0.9 (0.3; 1.4) 3.8 (3.1; 4.4) 5.5 (4.9; 6.2) À1.4 (À1.9; À0.9)</cell><cell>1.08 (1.07; 1.10) 1.01 (1.00; 1.02) eGFR/mGFR 0.98 (0.97; 1.00) 1.10 (1.09; 1.12) 0.99 (0.98; 1.00) 1.04 (1.03; 1.05) 1.07 (1.05; 1.08) 1.10 (1.09; 1.12) 1.00 (0.99; 1.01)</cell><cell>11.8 (11.2; 12.3) 9.6 (9.1; 10.2) RMSE 11.4 (10.8; 12.0) 12.8 (12.3; 13.3) 11.3 (10.8; 11.9) 11.3 (10.7; 11.9) 12.9 (12.2; 13.5) 13.8 (13.1; 14.5) 9.8 (9.3; 10.3)</cell><cell>0.85 (0.84; 0.86) 0.87 (0.86; 0.88) Lin's CCC 0.82 (0.81; 0.84) 0.81 (0.79; 0.83) 0.81 (0.79; 0.82) 0.84 (0.82; 0.85) 0.83 (0.81; 0.84) 0.81 (0.79; 0.82) 0.87 (0.86; 0.88)</cell><cell>40.0 (37.5; 42.5) 52.3 (49.8; 54.9) P10 (%) 42.1 (39.5; 44.6) 36.3 (33.8; 38.7) 42.1 (39.5; 44.6) 43.0 (40.5; 45.6) 38.1 (35.6; 40.6) 36.0 (33.6; 38.5) 50.5 (48.0; 53.1)</cell><cell>85.6 (83.8; 87.4) 92.4 (91.0; 93.7) P30 (%) 88.2 (86.6; 89.9) 80.0 (77.9; 82.0) 89.0 (87.4; 90.6) 88.2 (86.6; 89.9) 84.4 (82.6; 86.3) 82.0 (80.1; 84.0) 91.2 (89.8; 92.7)</cell><cell>mGFR &lt;60 mL/min/1.73 m 2 (n ¼ 753)</cell><cell>CKD-EPI combi BIS2* mGFR ¼ 42.9 FAS crea * CKD-EPI crea BIS1* FAS cysC * CKD-EPI cysC * CAPA FAS combi *</cell><cell>3.9 (3.1; 4.6) 1.8 (1.2; 2.3) eGFR -mGFR 0.7 (0.0; 1.3) 5.9 (5.1; 6.7) 1.7 (1.1; 2.4) 2.9 (2.2; 3.6) 2.7 (1.9; 3.5) 4.9 (4.1; 5.7) 1.4 (0.8; 1.9)</cell><cell>1.09 (1.07; 1.11) 1.06 (1.05; 1.08) eGFR/mGFR 1.04 (1.02; 1.06) 1.15 (1.12; 1.17) 1.07 (1.05; 1.09) 1.09 (1.07; 1.11) 1.06 (1.04; 1.08) 1.12 (1.10; 1.14) 1.05 (1.03; 1.07)</cell><cell>11.0 (10.0; 11.8) 7.9 (7.2; 8.6) RMSE 9.2 (8.4; 9.9) 13.0 (12.1; 13.8) 8.7 (8.0; 9.3) 9.8 (8.9; 10.6) 11.4 (10.3; 12.3) 12.1 (11.0; 13.2) 8.1 (7.4; 8.7)</cell><cell>0.73 (0.70; 0.76) 0.80 (0.78; 0.83) Lin's CCC 0.75 (0.71; 0.78) 0.65 (0.62; 0.69) 0.75 (0.72; 0.78) 0.73 (0.70; 0.76) 0.72 (0.69; 0.75) 0.69 (0.66; 0.72) 0.80 (0.77; 0.82)</cell><cell>35.5 (32.0; 38.9) 48.3 (44.8; 51.9) P10 (%) 41.2 (37.6; 44.7) 31.2 (27.9; 34.5) 42.5 (39.0; 46.0) 38.5 (35.0; 42.0) 35.5 (32.0; 38.9) 32.9 (29.6; 36.3) 47.9 (44.4; 51.5)</cell><cell>79.9 (77.1; 82.8) 89.1 (86.9; 91.3) P30 (%) 84.6 (82.0; 87.2) 69.5 (66.2; 72.8) 85.4 (82.9; 87.9) 83.4 (80.7; 86.1) 81.8 (79.0; 84.6) 78.2 (75.3; 81.2) 87.0 (84.6; 89.4)</cell><cell>mGFR !60 mL/min/1.73 m 2 (n ¼ 716)</cell><cell>CKD-EPI combi BIS2* mGFR ¼ 74.8 FAS crea CKD-EPI crea * BIS1 FAS cysC * CKD-EPI cysC * CAPA FAS combi *</cell><cell>5.2 (4.3; 6.0) À4.3 (À5.1; À3.6) eGFR -mGFR À6.1 (À6.9; À5.2) 3.3 (2.4; 4.2) À7.9 (À8.7; À7.1) À1.3 (À2.2; À0.4) 4.9 (3.9; 5.9) 6.2 (5.1; 7.2) À4.3 (À5.1; À3.5)</cell><cell>1.08 (1.07; 1.09) 0.95 (0.94; 0.96) eGFR/mGFR 0.93 (0.92; 0.94) 1.06 (1.04; 1.07) 0.90 (0.89; 0.91) 0.99 (0.98; 1.00) 1.07 (1.06; 1.09) 1.09 (1.08; 1.10) 0.95 (0.94; 0.96)</cell><cell>(10.3; 11.9) 12.5 (11.9; 13.2) 11.1 RMSE 13.3 (12.5; 14.1) 12.7 (12.1; 13.3) 13.6 (12.7; 14.4) (10.5; 12.1) 12.7 (11.8; 13.6) 14.3 (13.5; 15.0) 15.4 (14.4; 16.3) 11.3</cell><cell>(0.54; 0.63) 0.55 (0.50; 0.59) 0.59 Lin's CCC 0.49 (0.44; 0.54) 0.46 (0.40; 0.51) 0.44 (0.39; 0.49) (0.54; 0.63) 0.55 (0.49; 0.60) 0.50 (0.45; 0.55) 0.49 (0.44; 0.54) 0.59</cell><cell>(52.9; 60.2) 44.7 (41.0; 48.3) 56.6 P10 (%) 43.0 (39.4; 46.7) 41.6 (38.0; 45.2) 41.6 (38.0; 45.2) (49.5; 56.9) 47.8 (44.1; 51.4) 40.9 (37.3; 44.5) 39.2 (35.7; 42.8) 53.2</cell><cell>(94.3; 97.3) 91.5 (89.4; 93.5) 95.8 P30 (%) 92.0 (90.0; 94.0) 91.1 (89.0; 93.2) 92.9 (91.0; 94.8) (94.2; 97.2) 93.3 (91.5; 95.1) 87.2 (84.7; 89.6) 86.0 (83.5; 88.6) 95.7</cell><cell>equation (Scr-based with Q ¼ 0.70 mg/dL for females and Q ¼ 0.90 mg/dL for males; SCysC-based with Q 0 ¼ 0.95 mg/L). FAS combi is calculated for a ¼ 0.5.</cell></row></table><note><p><s>504H.</s><s>Pottel et al.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">u l l -a g e -s p e c t r u m c y s t a t i n C -b a s e d e G F R e q u a t i o n</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We also investigated the impact of the weighting factor a on the performance of the FAS equations by varying a (between 0 ¼ FAS cysC and 1 ¼ FAS crea ) and calculating the difference 'FAS -mGFR', on an individual basis.</s><s>Due to the way the FAS equations are designed, FAS crea % FAS cysC % FAS combi , in the case of the normalized biomarkers Scr/Q crea % ScysC/Q cysC .</s><s>When Scr/Q crea strongly deviates from ScysC/Q cysC , then FAS crea will strongly deviate from FAS cysc and FAS combi will lie in-between both single biomarker FAS predictions.</s><s>We found that, on an individual basis, in approximately one-third of the subjects, the FAS crea equation was closest to mGFR, in onethird of the subjects the FAS cysC equation had the lowest individual bias and in one-third the FAS combi equation was the best choice for a specific value of a.</s><s>In the latter, when mGFR lies between FAS crea and FAS cysC predictions, there is always a value of a for which FAS combi ¼ mGFR.</s><s>We realize that this analysis is mainly speculative as we do not know the optimal value of a in actual clinical situations, but the intention of this analysis was to evaluate in which conditions a preference for single biomarker FAS predictions or for the combined biomarker FAS prediction might exist.</s><s>Unfortunately, we could not identify specific conditions where one over the other equations was to be preferred (unless the situation where Scr/Q crea &lt;0.67).</s></p><p><s>The strength of this study is the large number of subjects (n ¼ 6132) covering the complete age span from 2 to 100 years of age.</s><s>This study partially used data from our previous study, where n ¼ 6870 subjects were used to validate the FAS crea equation.</s><s>Although both studies partially used the same subjects, the ScysC data was not part of the previous evaluation.</s><s>All ScysC concentrations were analysed with cystatin C assays based on the international certified standard or were back-calculated using calibration curves developed for that purpose.</s><s>The reference tests used in this study comprise all currently used direct measurement methods: 51 Cr-EDTA (plasma/renal clearance), inulin (renal clearance), iohexol (plasma clearance in its different configurations) and iothalamate (renal clearance), illustrating the diversity of mGFR results and demonstrating the robustness of the FAS construction.</s><s>Moreover, the cohorts used in this study were from different countries in Europe (Norway, Germany, France, Belgium) and the USA (Rochester, MN and the CRIC cohort), making the sample representative for the general Caucasian population and kidney disease population.</s></p><p><s>Our study has some limitations.</s><s>First, we did not incorporate different ancestries, and, therefore, this validation study is limited to Caucasians only.</s><s>Although it is known that creatinine generation (and thus Scr) is affected by ancestry, it is also known that ScysC is not influenced by differences in ancestry.</s><s>We always have claimed that using appropriate ancestry-specific normalization factors for Scr may solve this problem and consequently the FAS concept remains applicable.</s><s>Secondly, our goal was to validate the new FAS equations against mGFR and compare them with the existing and recommended equations, not to predict the risk of mortality.</s><s>Whether the FAS equations are better predictors of mortality is another topic and requires further studies using a different statistical methodology <ref type="bibr" target="#b25">[27]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C O N C L U S I O N S</head><p><s>The fundamental concept for the Scr-based FAS equation development, namely that mean GFR for healthy subjects evolves along an age-specific curve, and that deviation from that curve is related to the inverse of normalized Scr/Q crea , also holds true for normalized ScysC/Q cysC .</s><s>The current work shows that the FAS equations display better or equivalent prediction performance than the currently recommended eGFR equations, across the full age spectrum, both in normal and reduced kidney function.</s><s>The FAS equation is not only applicable to all ages, but also to all currently recommended renal biomarkers.</s><s>The FAS concept may also be applicable to other renal biomarkers, if appropriately normalized, but this remains to be proven once standardized assays are in place.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S U P P L E M E N T A R Y D A T A</head><p><s>Supplementary data are available online at http://ndt.oxfordjour nals.org.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">An estimating glomerular filtration rate equation for the full age spectrum</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pottel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hoste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dubourg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="798" to="806" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Glomerular filtration rate in healthy living potential kidney donors: a meta-analysis supporting the construction of the full age spectrum (FAS) equation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pottel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hoste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yayo</surname></persName>
		</author>
		<idno type="DOI">10.1159/000450893</idno>
	</analytic>
	<monogr>
		<title level="j">Nephron Clin Pract</title>
		<imprint>
			<date type="published" when="2016-10-21">2016. 2016 Oct 21</date>
		</imprint>
	</monogr>
	<note>Nephron. Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Estimating glomerular filtration rate from serum creatinine and cystatin C</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Inker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tighiouart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="20" to="29" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">First certified reference material for cystatin C in human serum ERM-DA471/IFCC</title>
		<author>
			<persName><forename type="first">A</forename><surname>Grubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blirup-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lindstro</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1619" to="1621" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Maier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="445" to="453" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator</title>
		<author>
			<persName><forename type="first">A</forename><surname>Grubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Horio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-O</forename><surname>Hansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="974" to="986" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Two novel equations to estimate kidney function in persons aged 70 years or older</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Schaeffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="471" to="481" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Appel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Chertow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="S148" to="S153" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Measuring glomerular filtration rate using 51Cr-EDTA</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pottel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hoste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Waele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucl Med Commun</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1150" to="1155" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Rule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lieske</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1169" to="1176" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kilbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eaglestone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="57" to="66" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A new equation to estimate the glomerular filtration rate in children, adolescents and young adults</title>
		<author>
			<persName><forename type="first">L</forename><surname>Hoste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dubourg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Selistre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="944" to="947" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Reference values for cystatin C serum concentrations in children</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bo ¨kenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Domanetzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zinck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Nephrol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="125" to="129" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">b-trace protein, cystatin C, b2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children</title>
		<author>
			<persName><forename type="first">G</forename><surname>Filler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Priem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lepage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="729" to="736" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance</title>
		<author>
			<persName><forename type="first">H</forename><surname>Finney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Newman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Price</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="49" to="59" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Age, gender, and race effects on cystatin C levels in US adolescents</title>
		<author>
			<persName><forename type="first">D</forename><surname>Groesbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ko ¨ttgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Parekh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1777" to="1785" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Biology of renal function and renal failure&quot; working group</title>
		<author>
			<persName><forename type="first">S</forename><surname>Se ´ronie-Vivien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pieroni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1664" to="1686" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS Survey</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Eckfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Karger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="888" to="893" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine</title>
		<author>
			<persName><forename type="first">A</forename><surname>Grubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Nyman</surname></persName>
		</author>
		<author>
			<persName><surname>Bjo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Clin Lab Invest</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="73" to="77" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: A cross-sectional study in Sweden</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bjo ¨rk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Larsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem Lab Med</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="403" to="414" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Clin Chem effects of glucocorticoid immunosuppression on serum cystatin c concentrations in renal transplant patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Risch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herklotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aha</forename><surname>Blumberg</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="2055" to="2059" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Cystatin C as a marker of GFRhistory, indications, and future research</title>
		<author>
			<persName><forename type="first">G</forename><surname>Filler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bo ¨kenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hofmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Residual associations of inflammatory markers with eGFR after accounting for measured GFR in a communitybased cohort without CKD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vtn</forename><surname>Stefansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="280" to="286" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The applicability of eGFR equations to different populations</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mariat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="513" to="522" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Estimated GFR is biased by non-traditional cardiovascular risk factors</title>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">M</forename><surname>Fuskeva ˚g</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Nephrol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="7" to="15" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Estimated glomerular filtration rate: fit for what purpose?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Warnock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephron</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="43" to="149" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gagneux-Brunon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delanaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Maillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1573" to="1581" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The role of cystatin C in improving GFR estimation in the general population</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">O</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">D</forename><surname>Mathisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Melsom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="32" to="40" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">New equations to estimate GFR in children with CKD</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muñoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="629" to="637" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A new equation to estimate glomerular filtration rate</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Schmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="604" to="612" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
